Advanced search
Publication Cover
Infection Ecology & Epidemiology Volume 3, 2013 - Issue 1
Submit an article Journal homepage
339
Views
1
CrossRef citations to date
0
Altmetric
Original Research Articles

Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine

Karlis PauksensSection of Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala, SwedenCorrespondence[email protected]
, MD, PhD
Article: 20766 | Received 04 Mar 2013, Accepted 23 Jul 2013, Published online: 30 Aug 2013

References

  • Radwan HM, Cheeseman SH, Lai KK, Ellison I. Influenza in human immunodeficiency virus-infected patients during the 1997–1998 influenza season. Clin Infect Dis. 2000; 31: 604–6.
  • Klein MB, Lu Y, DelBalso L, Boivin G. Influenza virus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis. 2007; 45: 234–40.
  • Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, etal. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2009; 58: 1–52.
  • Recommendations of the Swedish National Board of Health and Welfare: influenza vaccination (Socialstyrelsens allmänna råd. Vaccination mot influensa. SOFS 1997:21). Available from: http://www.socialstyrelsen.se/sosfs/1997-21.
  • World Health Organization director general Dr. Margaret Chan. Pandemic (H1N1) 2009 press briefings. News conference in Geneva. Media Centre Multimedia. Available from: http://www.who.int/mediacentre/multimedia/swineflupb_20090426/en/index.html [cited 29 April 2009].
  • Information from the Swedish Medical Products Agency. 2009; 20: 99. Available from: http://www.lakemedelsverket.se/upload/omlakemedelsverket/publikationer/information-fran-lakemedelsverket/Info_fr_LV_2009-5.
  • Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, etal. Ten years of experience with the trivalent split-influenza vaccine Fluarix. Clin Drug Invest. 2002; 22: 751–69.
  • The European Medicines Agency, Committee for Proprietary Medicinal Products. Guidelines on harmonization of requirements for influenza vaccines. Reference number CPMP/BWP/214/96. First published 3 December 1997. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
  • Bickel M, von Hentig N, Wieters I, Khaykin P, Nisius G, Haberl A, etal. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011; 52: 122–7.
  • Launa O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, etal. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis. 2011; 204: 124–34.
  • Soonawala D, Rimmelzwaan GF, Gelinck LBS, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One. 2011; 6: e16496.
  • Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine ; 28. 2009; 2010: 1740–5.
  • Nicholson KG, Abrama KR, Batham S, Clark TW, Hoschler K, Lim WS, etal. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect ; 11. 2009; 2011: 91–101.
  • Crum-Cianflore NF, Iverson E, Defang G, Blair PJ, Eberly LE, Maguire J, etal. Durability of antibody responses after receipt of the monovalent pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine ; 29. 2009; 2001: 3183–91.
  • Cagigi A, Nilsson A, Pensieroso S, Chiodi F. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis. 2010; 10: 499–503.
  • Durier C, Desaint C, Lucht F, Girard PM, Levy Y, May T, etal. Long-term immunogenicity of two doses of A/H1N1v vaccine with and without AS03A adjuvant in HIV-infected adults. AIDS ; 27. 2009; 2013: 87–9.
  • Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, etal. Response to pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Vaccine ; 29. 2009; 2011: 9209–13.
  • Cooper C, Thorne A, Klein M, Conway M, Boivin M, Haase D, etal. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomised trial of HIV infected adults. PLoS One. 2011; 6: e17758.
  • Ljungman P, Hahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of vaccine: a randomised study. Br J Haematol. 2005; 130: 96–8.
  • Cooper CL. Pandemic H1N1 influenza and HIV: a review of natural history, management and vaccine immunogenicity. Curr Opin Infect Dis ; 25. 2009; 2012: 26–35.
  • Information from the Swedish Medical Products Agency. Available from: http://www.lakemedelsverket.se/Alla-nyheter/NYHETER-2012/Pandemrix-narkolepsi/ [cited 1 June 2012].

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.